

NOEVIR HOLDINGS

◆ Noevir Holdings Co., Ltd. Public & Investor Relations
7-6-15 Ginza Chuo-ku, Tokyo 104-8208, Japan

March 19, 2013

Notice Regarding Integration of Noevir Group Companies' R&D Divisions

Trade name: Noevir Holdings Co., Ltd.
Representative: Takashi Okura, President and Representative Director
(Security Code Number: 4928; TSE, First Section)
Contact: Takashi Oyama, Senior Executive Officer in charge of Corporate Affairs
Tel: +81-78-303-5101

At board of directors' meetings held today by both Noevir Co., Ltd. and TOKIWA Pharmaceutical Co., Ltd., companies of the Noevir Group, the two companies decided to integrate their R&D divisions.

On April 1, 2013, the organization and operation of both companies' R&D divisions will be integrated, and, under the organizational base of Noevir Co., Ltd., a new research organization will be set up and started that will play the part of a comprehensive R&D center for the entire Noevir Group.

To adapt to the recent rapidly changing business environment surrounding cosmetic, pharmaceutical, and food markets, the new structure will expand our R&D domain by building stronger relationships with universities, medical institutions, and other organizations that possess advanced technology. Further, by accurately understanding the further diversification of customer needs, the Noevir Group will continue to provide a continuous stream of high-quality and value-added products that are market competitive.